VRDN-002

• Description:

  VRDN-002 is a human monoclonal antibody (mAb) targeting IGF1R/CD221. VRDN-002 reduces inflammation and proptosis in thyroid eye disease (TED) . VPI-2690B can be used in Graves ophthalmopathy research[1].

• UNSPSC:

  12352203

• Target:

  IGF-1R

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Smiles:

  [VRDN-002]

• References & Citations:

  [1]Dickinson B. VRDN-002, a second-generation insulin like growth factor-1 receptor (IGF-1R) inhibitory antibody for thyroid eye disease: Preclinical pharmacokinetics and clinical promise[J]. Investigative Ophthalmology & Visual Science, 2022, 63 (7) : 3995–A0337-3995–A0337.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  No Development Reported